Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. develops targeted cancer therapies as a clinical-stage biopharmaceutical company, with news centered on antibody-drug conjugate programs and related financial updates. Its principal update themes include SIM0505, a Cadherin-6-directed ADC with a topoisomerase 1 inhibitor payload, and LNCB74, a B7-H4-directed ADC.
Company announcements also cover clinical data presentations, FDA interactions such as Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, collaborations with Simcere Zaiming, business updates, financial results, and participation in healthcare investor conferences.
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical firm, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th. The presentation will be pre-recorded and available via an audio webcast on the company’s website, with replays accessible for 30 days post-event. NextCure is focused on developing novel immunomedicines aimed at treating cancer and immune-related diseases, particularly for patients not responding to current therapies. Their proprietary FIND-IO™ platform facilitates research into immune cell targets.
NextCure, a clinical-stage biopharmaceutical company focused on developing novel immunomedicines for cancer, announced its participation in the 19th Annual Morgan Stanley Global Healthcare Conference on September 9th at 12:30 PM ET. Investors can access a live audio webcast on NextCure's website, with a replay available for 30 days post-event. The company uses its FIND-IO™ platform to discover immune cell targets, aiming to provide new therapies for patients unresponsive to current treatments.
NextCure, Inc. (Nasdaq: NXTC) reported its Q2 2021 financial results, showcasing progress in clinical trials, including the NC318 Phase 2 monotherapy trial. Key updates include resumed enrollment in NSCLC adenocarcinoma and a revised dosing regimen aimed at enhancing drug exposure. Financially, cash and equivalents decreased to $249.5 million, while net loss rose to $18.0 million due to increased operational costs. The company anticipates data updates from ongoing trials and expects its funds to last through the second half of 2023.
NextCure, Inc. (Nasdaq: NXTC) has commenced a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody targeting advanced solid tumors. Michael Richman, CEO, affirmed this trial extends their innovative immunomedicine pipeline for cancers inadequately treated by existing therapies. The trial evaluates NC762's safety and tolerability, with initial data expected by mid-2022. NC762 aims to inhibit tumor growth through a unique mechanism, with applications across several cancer types, including non-small cell lung cancer.
NextCure has published preclinical data on NC410, a novel immunomedicine targeting collagen-rich tumors, in the journal eLife. This treatment, currently in a Phase 1/2 clinical trial for advanced solid tumors, aims to block immune suppression via LAIR-1. Preclinical studies show that NC410 promotes T cell activity and may be effective as a monotherapy or in combination with checkpoint inhibitors. Initial clinical data is expected in the second half of 2021, offering potential hope for patients with resistant cancers.
NextCure, Inc. (Nasdaq: NXTC) announced its participation in a fireside chat at the JMP Securities Life Sciences Conference on June 17 at 1:30 pm Eastern time. Interested investors can access the live audio webcast on its website, with a replay available afterward for 30 days. NextCure is focused on developing first-in-class immunomedicines to treat cancer and other immune-related diseases through its proprietary FIND-IO™ platform, aiming to provide new treatments for patients resistant to current therapies.
NextCure, a clinical-stage biopharmaceutical company, announced that Dr. Martin Gutierrez will present a Trials in Progress poster for NC410 at the 2021 ASCO Annual Meeting. NC410 targets collagen-rich areas in tumors, acting as a LAIR-1 decoy to enhance immune responses. Preliminary studies indicate significant anti-tumor activity across multiple cancer types, including gastric and ovarian cancers. The Phase 1/2 study aims to assess safety and preliminary efficacy, with initial clinical data expected in late 2021.
NextCure, Inc. (Nasdaq: NXTC) reported its Q1 2021 financial results, showing a net loss of $16.5 million compared to a net income of $9.7 million in Q1 2020. The company’s cash reserves decreased to $268.2 million, down from $283.4 million at year-end 2020, impacted by operational expenditures. Notably, no revenue was generated in Q1 2021, a decline from $22.4 million the previous year. The company remains focused on its clinical programs, with ongoing trials for NC318, NC410, and NC762, and expects to fund operations into the second half of 2023.
NextCure, a clinical-stage biopharmaceutical company (Nasdaq: NXTC), will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 12 at 2:00 pm ET. The event will showcase NextCure's commitment to developing innovative immunomedicines for cancer and immune-related diseases, leveraging their proprietary FIND-IO™ platform. A live audio webcast will be accessible via their website, with a replay available for 30 days post-event.
NextCure, Inc. (Nasdaq: NXTC) announced its participation in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5th at 2:40 PM Eastern time. The event will be accessible via a live audio webcast on the company’s website, with a replay available for 30 days post-event.
NextCure focuses on developing first-in-class immunomedicines for cancer and immune-related diseases using its FIND-IO™ platform. The company aims to provide new treatments for patients unresponsive to existing therapies.